Charan Rakshita A, LaVoie Matthew J
Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA.
Mol Cell Neurosci. 2015 May;66(Pt A):62-71. doi: 10.1016/j.mcn.2015.02.008. Epub 2015 Feb 17.
Mutations in the E3 ligase parkin are the most common cause of autosomal recessive Parkinson's disease (PD), but it is believed that parkin dysfunction may also contribute to idiopathic PD. Since its discovery, parkin has been implicated in supporting multiple neuroprotective pathways, many revolving around the maintenance of mitochondrial health quality control and governance of cell survival. Recent advances across the structure, biochemistry, and cell biology of parkin have provided great insights into the etiology of parkin-linked and idiopathic PD and may ultimately generate novel therapeutic strategies to slow or halt disease progression. This review describes the various pathways in which parkin acts and the mechanisms by which parkin may be targeted for therapeutic intervention. This article is part of a Special Issue entitled 'Neuronal Protein'.
E3 泛素连接酶帕金蛋白(parkin)的突变是常染色体隐性帕金森病(PD)最常见的病因,但人们认为帕金蛋白功能障碍也可能与特发性 PD 有关。自发现以来,帕金蛋白一直被认为在支持多种神经保护途径中发挥作用,其中许多途径围绕线粒体健康质量控制的维持和细胞存活的调控。最近在帕金蛋白的结构、生物化学和细胞生物学方面的进展,为深入了解帕金蛋白相关和特发性 PD 的病因提供了很大帮助,并最终可能产生减缓或阻止疾病进展的新治疗策略。本综述描述了帕金蛋白发挥作用的各种途径以及针对帕金蛋白进行治疗干预的机制。本文是名为“神经元蛋白”的特刊的一部分。